6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Suppression I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Mucositis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Dermatologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
with O
peripheral B-Not_AE_Candidate
T I-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
( O
PTCL O
) O
treated O
with O
FOLOTYN O
were O
mucositis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
35 O
% O
) O
are O
mucositis O
, O
thrombocytopenia O
, O
nausea O
, O
and O
fatigue O
. O

Most O
common O
serious O
adverse O
reactions O
are O
pyrexia O
, O
mucositis O
, O
sepsis O
, O
febrile O
neutropenia O
, O
dehydration O
, O
dyspnea O
, O
and O
thrombocytopenia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allos O
Therapeutics O
, O
Inc O
at O
1-888-ALLOS88 O
( O
1-888-255-6788 O
) O
or O
www.FOLOTYN.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
of O
FOLOTYN O
was O
evaluated O
in O
111 O
PTCL B-Not_AE_Candidate
patients O
in O
a O
single-arm O
clinical O
study O
in O
which O
patients O
received O
a O
starting O
dose O
of O
30 O
mg/m O
2 O
once O
weekly O
for O
6 O
weeks O
in O
7-week O
cycles O
. O

The O
median O
duration O
of O
treatment O
was O
70 O
days O
( O
range O
1-540 O
days O
) O
. O

Most O
Frequent O
Adverse O
Reactions O
Table O
4 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
using O
the O
National O
Cancer O
Institute-Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
NCI O
CTCAE O
, O
version O
3.0 O
) O
. O

Table O
4 O
Adverse O
Reactions O
Occurring O
in O
PTCL O
Patients O
( O
Incidence O
> O
= O
10 O
% O
of O
patients O
) O
N=111 O
Total O
Grade O
3 O
Grade O
4 O
Preferred O
Term O
N O
% O
N O
% O
N O
% O
a O
Stomatitis B-OSE_Labeled_AE
or O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the O
gastrointestinal I-OSE_Labeled_AE
and O
genitourinary O
tracts I-OSE_Labeled_AE
. O

bFive O
patients O
with O
platelets B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
c O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
, O
aspartate O
aminotransferase O
, O
and O
transaminases O
increased I-OSE_Labeled_AE
Any O
Adverse O
Event O
111 O
100 O
48 O
43 O
34 O
31 O
Mucositis B-OSE_Labeled_AE
a O
78 O
70 O
19 O
17 O
4 O
4 O
Thrombocytopenia B-OSE_Labeled_AE
b O
45 O
41 O
15 O
14 O
21 O
19 O
b O
Nausea B-OSE_Labeled_AE
44 O
40 O
4 O
4 O
0 O
0 O
Fatigue B-OSE_Labeled_AE
40 O
36 O
5 O
5 O
2 O
2 O
Anemia B-OSE_Labeled_AE
38 O
34 O
17 O
15 O
2 O
2 O
Constipation B-OSE_Labeled_AE
37 O
33 O
0 O
0 O
0 O
0 O
Pyrexia B-OSE_Labeled_AE
36 O
32 O
1 O
1 O
1 O
1 O
Edema B-OSE_Labeled_AE
33 O
30 O
1 O
1 O
0 O
0 O
Cough B-OSE_Labeled_AE
31 O
28 O
1 O
1 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
29 O
26 O
0 O
0 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
28 O
25 O
2 O
2 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
27 O
24 O
14 O
13 O
8 O
7 O
Diarrhea B-OSE_Labeled_AE
23 O
21 O
2 O
2 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
21 O
19 O
8 O
7 O
0 O
0 O
Anorexia B-OSE_Labeled_AE
17 O
15 O
3 O
3 O
0 O
0 O
Hypokalemia B-OSE_Labeled_AE
17 O
15 O
4 O
4 O
1 O
1 O
Rash B-OSE_Labeled_AE
17 O
15 O
0 O
0 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
16 O
14 O
2 O
2 O
0 O
0 O
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
15 O
14 O
1 O
1 O
0 O
0 O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
c O
14 O
13 O
6 O
5 O
0 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
13 O
12 O
4 O
4 O
0 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
13 O
12 O
0 O
0 O
0 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
12 O
11 O
3 O
3 O
0 O
0 O
Leukopenia B-OSE_Labeled_AE
12 O
11 O
3 O
3 O
4 O
4 O
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
12 O
11 O
0 O
0 O
0 O
0 O
Asthenia B-OSE_Labeled_AE
11 O
10 O
1 O
1 O
0 O
0 O
Tachycardia B-OSE_Labeled_AE
11 O
10 O
0 O
0 O
0 O
0 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
11 O
10 O
1 O
1 O
0 O
0 O
Serious O
Adverse O
Events O
Forty-four O
percent O
of O
patients O
( O
n O
= O
49 O
) O
experienced O
a O
serious O
adverse O
event O
while O
on O
study O
or O
within O
30 O
days O
after O
their O
last O
dose O
of O
FOLOTYN O
. O

The O
most O
common O
serious O
adverse O
events O
( O
> O
3 O
% O
) O
, O
regardless O
of O
causality O
, O
were O
pyrexia B-OSE_Labeled_AE
, O
mucositis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

One O
death B-NonOSE_AE
from O
cardiopulmonary B-NonOSE_AE
arrest I-NonOSE_AE
in O
a O
patient O
with O
mucositis B-NonOSE_AE
and O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
was O
reported O
in O
this O
trial O
. O

Deaths B-NonOSE_AE
from O
mucositis B-NonOSE_AE
, O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
and O
pancytopenia B-NonOSE_AE
occurred O
in O
1.2 O
% O
of O
patients O
treated O
on O
all O
FOLOTYN O
trials O
at O
doses O
ranging O
from O
30 O
to O
325 O
mg/m O
2 O
. O

Discontinuations O
Twenty-three O
percent O
of O
patients O
( O
n O
= O
25 O
) O
discontinued O
treatment O
with O
FOLOTYN O
due O
to O
adverse O
reactions O
. O

The O
adverse O
reactions O
reported O
most O
frequently O
as O
the O
reason O
for O
discontinuation O
of O
treatment O
were O
mucositis B-OSE_Labeled_AE
( O
6 O
% O
, O
n O
= O
7 O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
5 O
% O
, O
n O
= O
5 O
) O
. O

Dose O
Modifications O
The O
target O
dose O
of O
FOLOTYN O
was O
30 O
mg/m O
2 O
once O
weekly O
for O
6 O
weeks O
in O
7-week O
cycles O
. O

The O
majority O
of O
patients O
( O
69 O
% O
, O
n O
= O
77 O
) O
remained O
at O
the O
target O
dose O
for O
the O
duration O
of O
treatment O
. O

Overall O
, O
85 O
% O
of O
scheduled O
doses O
were O
administered O
. O

6.2 O
Post O
Marketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Dermatologic O
Reactions O
Toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
sometimes O
fatal B-NonOSE_AE
, O
has O
been O
reported O
during O
post-marketing O
use O
of O
FOLOTYN O
. O

Fatal B-NonOSE_AE
cases O
have O
been O
reported O
following O
the O
first O
dose O
of O
FOLOTYN O
, O
including O
when O
a O
reduced O
dose O
is O
given O
, O
and O
have O
been O
reported O
in O
patients O
with O
end B-Not_AE_Candidate
- I-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
undergoing O
dialysis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

